Company Thesis
The FDA’s AdCom meeting this October with regards to a clinical review of Makena’s updated efficacy and safety profiles is likely to result in a total withdrawal of the product from the market. On the other hand, Amag's (AMAG) recent Vyleesi launch for the treatment of HSDD in pre-menopausal women is likely to have been severely underestimated by investors. Each 10% of net addressable market for Vyleesi (in terms of prescription volume) are likely to result in $260 million in annual revenues and at least $20.8 million in recurring EBITDA .